Daclatasvir + Cyclosporine = Precautionary

Effect on Concentration

Daclatasvir
Increase
Applies within class?
No
Cyclosporine
No change
Applies within class?
No

Pharmacologic Effects

Daclatasvir
Effect
N/A
Applies within class?
No
Cyclosporine
Effect
N/A
Applies within class?
No

Interaction History

N/A

Last Updated 09-Jul-2018

Summary

Cyclosporine exposure was not affected by coadministration with DCV, however the AUC for DCV was increased by 40%, therefore caution is warranted when utilizing this combination. No dose adjustments are required.

Sources

Daclatasvir vs Cyclosporine ^

Study Design

*This interaction has not been formerly studied, but inferences are drawn from knowledge of the metabolic and transport pathways of each of the drugs.

Study Results

The manufacturer states that coadministration of daclatasvir with inhibitors or inducers of either CYP3A or P-gP may alter daclatasvir concentrations.

Study Conclusions

Inhibitors of P-gP or CYP3A may increase daclatasvir concentrations, while inducers of this enzyme and transport protein may decrease daclatasvir concentrations.

References

Garimella T, You X, Wang R, Huang SP, Kandoussi H, Biffano M, Eley T. A review of daclatasvir drug-drug interactions. Advances In Therapy. 2016; 11: 1867-1884.